Evidence map›Paper›PMID 38050084›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2024

A Murine Model of Vesicant-Induced Acute Lung Injury.

Iram Zafar, Shajer Manzoor, Nithya Mariappan, Shama Ahmad, Mohammad Athar, Veena Antony, Aftab Ahmad

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Acepromazine Reduces Airway Contraction in a Murine Model of Asthma.Clinical and experimental pharmacology & physiology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Iram ZafarDepartments of Anesthesiology and Perioperative Medicine (I.Z., S.M., S.A., A.A.), Department of Dermatology (M.A.), and Department of Medicine (V.A.), University of Alabama at Birmingham, Birmingham, Alabama.
Shajer ManzoorDepartments of Anesthesiology and Perioperative Medicine (I.Z., S.M., S.A., A.A.), Department of Dermatology (M.A.), and Department of Medicine (V.A.), University of Alabama at Birmingham, Birmingham, Alabama.
Nithya MariappanDepartments of Anesthesiology and Perioperative Medicine (I.Z., S.M., S.A., A.A.), Department of Dermatology (M.A.), and Department of Medicine (V.A.), University of Alabama at Birmingham, Birmingham, Alabama.
Shama AhmadDepartments of Anesthesiology and Perioperative Medicine (I.Z., S.M., S.A., A.A.), Department of Dermatology (M.A.), and Department of Medicine (V.A.), University of Alabama at Birmingham, Birmingham, Alabama.
Mohammad AtharDepartments of Anesthesiology and Perioperative Medicine (I.Z., S.M., S.A., A.A.), Department of Dermatology (M.A.), and Department of Medicine (V.A.), University of Alabama at Birmingham, Birmingham, Alabama.
Veena AntonyDepartments of Anesthesiology and Perioperative Medicine (I.Z., S.M., S.A., A.A.), Department of Dermatology (M.A.), and Department of Medicine (V.A.), University of Alabama at Birmingham, Birmingham, Alabama.
Aftab AhmadDepartments of Anesthesiology and Perioperative Medicine (I.Z., S.M., S.A., A.A.), Department of Dermatology (M.A.), and Department of Medicine (V.A.), University of Alabama at Birmingham, Birmingham, Alabama aftabahmad@uabmc.edu.ORCID https://orcid.org/0000-0003-0686-0987
University of Alabama at Birmingham · US

Funding

UAB Research Center of Excellence in ArsenicalsU54ES030246 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AUGELLI-SZAFRAN, CORINNE ELIZABETH · 2018 to 2022
$19.0M
Optimization of Novel Molecular Target-based Drugs for Arsenical Skin InjuryU01AR078544 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ATHAR, MOHAMMAD · 2020 to 2024
$3.9M
Novel lead compound advancement for mitigating halogen-induced mortality and morbidity.U01ES033263 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Shama Ahmad · 2022 to 2026
$3.6M
Extracellular RNA as therapeutic target after toxic chemical inhalationU01ES025069 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHMAD, AFTAB · 2014 to 2019
$2.5M
Targeting cardiopulmonary calpains to mitigate toxicity of halogen gases.U01ES028182 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHMAD, SHAMA, DELL'ITALIA, LOUIS J. · 2017 to 2019
$1.3M
Extracellular vesicles as mediators of injury in inhaled exposures to toxic chemicals.R56ES034423 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHMAD, AFTAB, AHMAD, SHAMA · 2023 to 2023
$446k
Airway stem cell activation in the mitigation of halogen-induced lung injuryR21ES030525 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHMAD, SHAMA · 2020 to 2021
$408k
Novel therapeutic targets for fluoroacetate-induced toxicities.R21ES032353 · NIEHS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AHMAD, AFTAB · 2020 to 2021
$408k
NIAMS NIH HHS U01 AR078544NIEHS NIH HHS R21 ES030525NIEHS NIH HHS R21 ES032353NIEHS NIH HHS R56 ES034423NIEHS NIH HHS U01 ES025069NIEHS NIH HHS U01 ES028182NIEHS NIH HHS U01 ES033263NIEHS NIH HHS U54 ES030246
6 · The paper itself

Abstract

Burn injuries including those caused by chemicals can result in systemic effects and acute lung injury (ALI). Cutaneous exposure to Lewisite, a warfare and chemical burn agent, also causes ALI. To overcome the limitations in conducting direct research on Lewisite-induced ALI in a laboratory setting, an animal model was developed using phenylarsine oxide (PAO) as a surrogate for Lewisite. Due to lack of a reliable animal model mimicking the effects of such exposures, development of effective therapies to treat such injuries is challenging. We demonstrated that a single cutaneous exposure to PAO resulted in disruption of the alveolar-capillary barrier as evidenced by elevated protein levels in the bronchoalveolar lavage fluid (BALF). BALF supernatant of PAO-exposed animals had increased levels of high mobility group box 1, a damage associated molecular pattern molecule. Arterial blood-gas measurements showed decreased pH, increased PaCO

Indexed as

Acute Lung InjuryArsenicalsIrritantsAnimalsBronchoalveolar Lavage FluidDisease Models, AnimalInterleukin-6LungMiceVascular Endothelial Growth Factor AArsenicalsInterleukin-6IrritantslewisiteoxophenylarsineVascular Endothelial Growth Factor A

Identifiers

PMID38050084
PMCPMC10801773
OpenAlexW4389167250

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.